Sponsored Links
| Abbott Japan And Eisai Receive Approval To Market The Pancreatic Digestive Enzyme Replacement Drug Lipacreon(R) (pancrelipase) In Japan |
 |
 |
 |
| Medical News - Cystic Fibrosis | |||
|
Abbott Japan Co., Ltd. and Eisai Co., Ltd. (TSE: 4523) announced today that they have received approval to market the pancreatic enzyme replacement drug Lipacreon(R)(pancrelipase) in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency (PEI)... Read more: Cystic Fibrosis News From Medical News Today
|